Table 3.
Model inputs: estimate of percentage of patients treated with medication for their condition (drug-treated patients) and number of patients currently treated with infliximab (Remicade)
| % | RA | AS | CD | UC | Psoriasis | PsA |
|---|---|---|---|---|---|---|
| Percentage of drug-treated patientsa | ||||||
| Germany | 48.75 | 48.75b | 63.55 | 81.20 | 32.89 | 48.75b |
| UK | 48.75 | 48.75b | 54.70 | 77.20 | 63.17 | 48.75b |
| Italy | 48.75 | 48.75b | 46.44 | 81.70 | 44.52 | 48.75b |
| The Netherlands | 48.75 | 48.75b | 58.94 | 77.40 | 44.46 | 48.75b |
| Belgium | 48.75 | 48.75b | 58.94 | 77.40 | 44.46 | 48.75b |
| Number of patients currently treated with infliximab (Remicade)c | ||||||
| Germany | 1925 | 1278 | 11,719 | 3835 | 1065 | 1918 |
| UK | 3160 | 485 | 6417 | 988 | 568 | 455 |
| Italy | 1840 | 1562 | 2188 | 2499 | 1388 | 2188 |
| The Netherlands | 1070 | 464 | 4214 | 1593 | 103 | 196 |
| Belgium | 1152 | 537 | 3838 | 1535 | 230 | 384 |
AS ankylosing spondylitis, CD Crohn’s disease, PsA psoriatic arthritis, RA rheumatoid arthritis, UC ulcerative colitis
aPharmapoint Rheumatoid Arthritis Global Forecast 2013–2022. Data on file. Values for Netherlands and Belgium were taken from a Western Europe average of France, Germany and United Kingdom treatment data
bRA data used as proxy
cIMS 2013. Data on file